Bitte verwenden Sie diesen Link, um diese Publikation zu zitieren, oder auf sie als Internetquelle zu verweisen:
https://hdl.handle.net/10419/46570
Kompletter Metadatensatz
DublinCore-Feld | Wert | Sprache |
---|---|---|
dc.contributor.author | Grossmann, Volker | en |
dc.date.accessioned | 2011-05-27 | - |
dc.date.accessioned | 2011-06-29T11:21:32Z | - |
dc.date.available | 2011-06-29T11:21:32Z | - |
dc.date.issued | 2011 | - |
dc.identifier.uri | http://hdl.handle.net/10419/46570 | - |
dc.description.abstract | This paper examines the role of both cost-sharing schemes in health insurance systems and entry regulation for pharmaceutical R&D expenditure, drug prices, aggregate productivity, and income. The analysis suggests that both an increase in the coinsurance rate and stricter price regulations adversely affect R&D spending in the pharmaceutical sector. In contrast, entry deregulation may lead to quality-improvements of pharmaceuticals, despite reducing price-setting power of pharmaceutical companies. Extension to an endogenous growth context suggests that, when individual labor supply depends on health status, both cost-sharing and entry barriers in the pharmaceutical sector also affect aggregate productivity and wage rates. | en |
dc.language.iso | eng | en |
dc.publisher | |aCenter for Economic Studies and ifo Institute (CESifo) |cMunich | en |
dc.relation.ispartofseries | |aCESifo Working Paper |x3439 | en |
dc.subject.jel | I10 | en |
dc.subject.jel | L10 | en |
dc.subject.jel | O30 | en |
dc.subject.ddc | 330 | en |
dc.subject.keyword | aggregate productivity | en |
dc.subject.keyword | cost-sharing | en |
dc.subject.keyword | entry deregulation | en |
dc.subject.keyword | health insurance | en |
dc.subject.keyword | pharmaceutical innovation | en |
dc.subject.stw | Pharmazeutische Forschung | en |
dc.subject.stw | Forschungsfinanzierung | en |
dc.subject.stw | Kostenbeteiligung | en |
dc.subject.stw | Gesetzliche Krankenversicherung | en |
dc.subject.stw | Markteintritt | en |
dc.subject.stw | Gesundheitsökonomik | en |
dc.subject.stw | Produktivität | en |
dc.subject.stw | Neue Wachstumstheorie | en |
dc.subject.stw | Theorie | en |
dc.title | Do cost-sharing and entry deregulation curb pharmaceutical Innovation? | - |
dc.type | Working Paper | en |
dc.identifier.ppn | 660775697 | en |
dc.rights | http://www.econstor.eu/dspace/Nutzungsbedingungen | en |
Datei(en):
Publikationen in EconStor sind urheberrechtlich geschützt.